je.st
news
Tag: opioid
Merck Announces Presentation of Phase 3 Results of Investigational Elbasvir/Grazoprevir in People with Chronic Hepatitis C Genotypes 1, 4 or 6 Infection Who Inject Drugs and Are on Opioid Agonist Therapy
2015-11-15 01:00:00| Merck.com - Research & Development News
Dateline City: KENILWORTH, N.J. Results from C-EDGE CO-STAR Presented at The Liver Meeting Show High Sustained Virologic Response After 12 Weeks of Treatment KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the presentation of results from the companys Phase 3 C-EDGE CO-STAR clinical trial evaluating the efficacy and safety of the investigational once-daily tablet elbasvir/grazoprevir1 (50mg/100mg) in patients with chronic hepatitis C virus (HCV) genotypes (GT) 1, 4 or 6 infection who inject drugs and are receiving opioid agonist therapy (OAT). Language: English Contact: MerckMedia Contacts:Doris Li, 908-246-5701Sarra Herzog, 201-669-6570orInvestor Contacts:Teri Loxam, 908-740-1986Justin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
UPDATE 2-BioDelivery's opioid treatment wins FDA approval
2015-10-27 05:17:53| Biotech - Topix.net
BioDelivery Sciences International Inc said the U.S. Food and Drug Administration had approved its opioid treatment for chronic pain, sending the drugmaker's shares up 23 percent in premarket trading on Monday. Belbuca is an opioid film patch and aims to treat patients with chronic pain who need round-the-clock treatment and for whom current alternatives do not suffice.
Tags: update
treatment
approval
wins
Prescription Opioid Deaths Level; Heroin-related Deaths Rise
2015-01-24 22:58:15| Biotech - Topix.net
The White House Office of National Drug Control Policy is announcing the 2013 drug overdose mortality data from the Centers for Disease Control and Prevention . The data show that drug deaths related to prescription opioids have remained stable since 2012, but the mortality rate associated with heroin increased for the third year in a row.
Tags: level
rise
prescription
deaths
MediciNova Announces New NIDA Grant for MN-166 (ibudilast) in Opioid Dependence
2014-09-08 02:29:34| Biotech - Topix.net
MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market and the JASDAQ Market of the Tokyo Stock Exchange , today announced that Columbia University and the New York State Psychiatric Institute was awarded new grant funding from the National Institute on Drug Abuse to continue clinical research on MN-166 in opioid dependence. The new grant will support the completion of a Phase 2a clinical trial of MN-166 in opioid dependence, for which positive interim results were previously reported by MediciNova on August 18, 2014.
Tags: grant
dependence
announces
opioid
Systematic Method Development Of UPC2 Conditions Using Opioid Drugs
2014-08-12 11:42:57| drugdiscoveryonline Downloads
This application note uses a panel of natural and synthetic opioid drugs to demonstrate the use of a systematic screening strategy for UPC2 method development.By Jonathan P. Danaceau, Kenneth J. Fountain, and Erin E. Chambers, Waters Corporation
Tags: conditions
development
method
drugs
Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] next »